Mounjaro and Male Fertility: What We Know, What We Don't

What obesity does to male fertility, the established science

Before asking what Mounjaro does to male fertility, it helps to start where the evidence is clearest: what excess weight does on its own. The relationship between obesity and reduced male fertility is well-documented. Higher body fat raises oestrogen levels relative to testosterone, which can suppress the production of the hormones (LH and FSH) that drive sperm development. Sperm concentration, motility and morphology are all measurably worse, on average, in men with a BMI above 30 compared with men in a healthy weight range, according to research published in reproductive medicine journals and summarised in NHS obesity guidance.

Heat is also a factor. Fat around the groin and thighs raises scrotal temperature, and sperm production is temperature-sensitive. This is not a fringe concern, it is one reason male-factor infertility workups routinely include weight as a variable. The broader picture of how Mounjaro affects fertility touches on some of these mechanisms in more detail.

The practical implication is that significant weight loss (however it is achieved) tends to improve testosterone levels and sperm parameters in men with obesity, a pattern that also emerges from the Mounjaro PCOS study, which explored how the drug interacts with hormonal and metabolic conditions beyond straightforward weight reduction. That background matters when thinking about tirzepatide: any medicine that produces sustained weight reduction may carry indirect reproductive benefits, even if it has never been tested for that purpose directly.

What the tirzepatide trial data actually say about male reproductive outcomes

This is where the honest answer gets uncomfortable. The SURMOUNT programme (the large-scale clinical trials that led to tirzepatide's UK weight-management licence) enrolled thousands of adults, and the headline results were striking: around 20–21% average weight loss at the 15mg dose over 72 weeks, as published in the SURMOUNT-1 trial in the New England Journal of Medicine. Those trials measured cardiovascular markers, metabolic markers, quality of life and side-effect profiles in detail.

Male reproductive endpoints were not among the primary or secondary outcomes. There is no trial sub-analysis of sperm count before and after tirzepatide. There is no published data on testosterone trajectories specifically attributable to the drug rather than the weight loss it produces. The Mounjaro SmPC on the eMC (the authoritative clinical document) does not list impaired male fertility as a known risk, but absence of a warning is not the same as evidence of safety; it reflects the absence of study rather than a clean bill of health.

For men considering treatment who want to become fathers, our dedicated page on Mounjaro and male fertility explores the specific questions clinicians are most likely to weigh up in that conversation.

What this means if you are trying to conceive

The position for men is meaningfully different from the guidance for women. For women who are pregnant, breastfeeding or actively trying to conceive, the MHRA and the Mounjaro prescribing information are unambiguous: treatment is not recommended, and a washout period applies before attempting pregnancy. That is a clear contraindication. The picture for men trying to father a child is not the same (there is no equivalent warning in the SmPC) but the absence of a specific caution does not mean the question can be skipped.

A sensible clinical conversation about tirzepatide and male fertility would cover: whether baseline fertility has been assessed, how urgently conception is being attempted, whether the metabolic benefits of weight loss might themselves improve reproductive outcomes over a meaningful timescale, and whether any other medicines being taken interact with Mounjaro. There is guidance on some of these questions at our page on whether Mounjaro affects fertility.

Your pen sits in the fridge door alongside things you open every morning, it is worth having the fertility question settled before you start that routine, not halfway through a course of treatment. Raise it with your prescriber at the consultation stage. If you are under a fertility specialist, looping them in is sensible too.

How to get a thorough clinical review before starting treatment

Mounjaro is a prescription-only medicine. A prescriber (not a checkout process) decides whether it is appropriate for your specific situation, including reproductive health considerations you raise. At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber the same day, and you can flag fertility questions directly in your consultation form. That is the right place to have this conversation: on the record, with a clinician who can weigh your full picture.

If you want to understand the wider treatment landscape first, the weight-loss treatment overview sets out what is currently licensed in the UK and how each option works. For men with questions specific to their situation, the Mounjaro fertility hub is a good starting point. You can also read about how Mounjaro works in detail (mechanism, dosing schedule, clinical evidence) before deciding whether to proceed to a consultation.

The NHS notes that weight loss itself, through diet and activity, can improve fertility markers in men with obesity, as part of its obesity treatment guidance. Mounjaro is one medically supervised route to that weight loss, but whether it is right for you, right now, given where you are in a fertility journey, is a clinical judgement. Speak to our prescribers and make sure the fertility question is part of the conversation from the start.